Portrai — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Portrai is a private, early-stage biotech leveraging AI and spatial biology to transform drug discovery and development. The company's platform analyzes layers of spatial transcriptomic, imaging, and genomic data from biological tissues to uncover new biological insights and identify valuable drug candidates. Founded by a team of Seoul National University professors and clinicians, Portrai is positioned at the convergence of AI, spatial omics, and therapeutics. The company is currently pre-revenue and focused on platform development and early pipeline asset generation.

AntibodiesBiologics

Technology Platform

AI-powered platform integrating spatial transcriptomics, tissue imaging, and genomic data to generate novel insights for drug discovery and repurposing.

Opportunities

The convergence of AI and spatial biology represents a massive, growing market to improve the inefficient drug discovery process.

Portrai's focus on the tissue microenvironment positions it well for complex diseases like oncology and immunology.

The drug repurposing application offers a potential path to faster, lower-risk revenue.

Risk Factors

The company is at an early, pre-revenue stage with unproven technology validation.

It faces intense competition from well-funded AI-biotech peers and must overcome the scientific challenge of translating spatial insights into successful clinical candidates.

Its operational split between the U.S.

and South Korea may present management complexities.

Competitive Landscape

Portrai competes in the broad AI-driven drug discovery space with companies like Recursion, Exscientia, and Insilico Medicine. Its specific focus on spatial biology data layers differentiates it, but it also faces competition from spatial omics tool providers (e.g., 10x Genomics, NanoString/Avalon) and large pharma with internal AI initiatives. Its academic-founder model is both a strength and a potential scaling challenge.

More companies in Biologics / Biosimilars →More companies in United States →